CYP2A13 genetic polymorphism in French Caucasian, Gabonese and Tunisian populations

Xenobiotica

Volumn 35, Issue 7, 2005, Pages 661-669

  Cauffiez, C ^a   Pottier, N ^a   Tournel, G ^a   Lo Guidice, J M ^a   Allorge, D ^a   Chevalier, D ^a   Migot Nabias, F ^b,c   Kenani, A ^d   Broly, F ^a  

^a UNIV LILLE   (France)

^b INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (Senegal)

^c CENTRE INTERNATIONAL DE RECHERCHES MÉDICALES DE FRANCEVILLE   (Gabon)

^d UNIVERSITY OF MONASTIR   (Tunisia)

Author keywords

CYP2A13; Cytochrome P450; Genetic polymorphism; Genotype

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 2A13; GENOMIC DNA; NITROSAMINE; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ADOLESCENT; ADULT; ARTICLE; ASIAN; CANCER INCIDENCE; CAUCASIAN; CHINESE; ETHNIC DIFFERENCE; FEMALE; FRANCE; GABON; GENE FREQUENCY; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HISPANIC; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; LUNG CARCINOGENESIS; MALE; NEGRO; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; RESPIRATORY SYSTEM; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SCHOOL CHILD; SINGLE STRAND CONFORMATION POLYMORPHISM; TOBACCO; TUNISIA; VOLUNTEER;

NICOTIANA TABACUM;

EID: 26644449191     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250500202171     Document Type: Article

References (19)

1. Cauffiez C, Lo-Guidice JM, Quaranta S, Allorge D, Chevalier D, Cenee S, Hamdan R, Lhermitte M, Lafitte JJ, Libersa C, et al. 2004. Genetic polymorphism of the human cytochrome CYP2A13 in a French population: Implication in lung cancer susceptibility. Biochemical and Biophysical Research Communications 317:662-669.
2. Chen Y, Liu YQ, Su T, Ren X, Shi L, Liu D, Gu J, Zhang QY, Ding X. 2003. Immunoblot analysis and immunohistochemical characterization of CYP2A expression in human olfactory mucosa. Biochemistry and Pharmacology 66:245-251.
3. Cheng XY, Chen GL, Zhang WX, Zhou G, Wang D, Zhou HH. 2004. Arg257Cys polymorphism of CYP2A13 in a Chinese population. Clinica et Chimica Acta 343:213-216.
4. Day DA, Tuite MF. 1998. Post-transcriptional gene regulatory mechanisms in eukaryotes: An overview. Journal of Endocrinology 157:361-371.
5. Ding X, Kaminsky LS. 2003. Human extrahepatic cytochromes P450: Function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annual Review in Pharmacology and Toxicology 43:149-173.
6. Fujieda M, Yamazaki H, Kiyotani K, Muroi A, Kunitoh H, Dosaka-Akita H, Sawamura Y, Kamataki T. 2003. Eighteen novel polymorphisms of the CYP2A13 gene in Japanese. Drug Metabolism and Pharmacokinetics 18:86-90.
7. Gotoh O. 1992. Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. Journal of Biological Chemistry 267:83-90.
8. Gu J, Su T, Chen Y, Zhang QY, Ding X. 2000. Expression and biotransformation enzymes in human fetal olfactory mucosa: Potential roles in developmental toxicity. Toxicology and Applied Pharmacology 165:158-162.
9. Hukkanen J, Pelkonen O, Raunio H. 2001. Expression of xenobiotic-metabolizing enzymes in human pulmonary tissue: Possible role in susceptibility for ILD. European Respiration Journal 32(Suppl.):122s-126s.
10. Ingelman-Sundberg M. 2001. Pharmacogenetics: An opportunity for a safer and more efficient pharmacotherapy. Journal of Internal Medicine 250:186-200.
11. Jiang JH, Jia WH, Chen HK, Feng BJ, Qin HD, Pan ZG, Shen GP, Huang LX, Feng QS, Chen LZ, et al. 2004. Genetic polymorphisms of CYP2A13 and relationship to nasopharyngeal carcinoma in Cantonese population. Journal of Translational Medicine 2:24.
12. Nebert DW, Menon AG. 2001. Pharmacogenomics, ethnicity, and susceptibility genes. Pharmacogenomics Journal 1:19-22.
13. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, et al. 1996. P450 superfamily: Update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6:1-42.
14. Rendic S. 2002. Summary of information on human CYP enzymes: Human cytochrome P450 metabolism data. Drug Metabolism Reviews 34:83-448.
15. Su T, Bao Z, Zhang QY, Smith TJ, Hong JY, Ding X. 2000. Human cytochrome P450 CYP2A13: Predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-methylnitroso-1-(3-pyridyl)-1-butanone. Cancer Research 60:5074-5079.
16. Wang H, Tan W, Hao B, Miao X, Zhou G, He F, Lin D. 2003 Substantial reduction in risk of lung adenocarcinoma associated with genetic polymorphism in CYP2A13, the most active cytochrome P450 for the metabolic activation of tobacco-specific carcinogen NNK. Cancer Research 63:8057-8061.
17. Zhang X, Caggana M, Cutler TL, Ding X. 2004. Development of a real-time polymerase chain reaction-based method for the measurement of relative allelic expression and identification of CYP2A13 alleles with decreased expression in human lung. Journal of Pharmacology and Experimental Therapy 311:373-381.
18. Zhang X, Chen Y, Liu Y, Ren X, Zhang QY, Caggana M, Ding X. 2003. Single nucleotide polymorphisms of the human cyp2a13 gene: Evidence for a null allele. Drug Metabolism and Disposition 31:1081-1085.
19. Zhang X, Su T, Zhang QY, Gu J, Caggana M, Li H, Ding X. 2002. Genetic polymorphisms of the human CYP2A13 gene: Identification of single-nucleotide polymorphisms and functional characterization of an Arg257Cys variant. Journal of Pharmacology and Experimental Therapy 302:416-423.